[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"NeuroTrauma Sciences, LLC\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100650025","phase-2-a-phase-2a-study-to-evaluate-the-dose-response-safety-tolerability-efficacy-and-population-pharmacokinetics-of-intravenous-nts-521-infusions-in-the-early-recovery-treatment-from-acute-ischemic-stroke-100650025",false,"NCT07742098","A Phase 2a Study to Evaluate the Dose-response, Safety, Tolerability, Efficacy, and Population Pharmacokinetics of Intravenous NTS-521 Infusions in the Early Recovery Treatment From Acute Ischemic Stroke","A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm Domain Within the ACT-GLOBAL Trial Platform, to Evaluate the Dose-response, Safety, Tolerability, Efficacy, and Population Pharmacokinetics of Intravenous NTS-521 Infusions in the Early Recovery Treatment From Acute Ischemic Stroke","ACT-IVATE","Inclusion Criteria:\n\n* Acute ischemic stroke with moderate to severe hemiparesis\n* Functional independence in activities of daily living without requiring nursing care before the index stroke.\n* Consent process by participant or proxy, with reconsent provision.\n* Age ≥ 45 to ≤ 80 years of age (inclusive) on the date of randomization\n* Sufficient attention, comprehension, and cooperation to carry out instructions\n\nExclusion Criteria:\n\n* Pre-existing motor deficit prior to index stroke\n* Posterior circulation ischemic stroke\n* Lacunar stroke\n* Qualifying brain imaging demonstrating intracranial hemorrhage, malignant middle cerebral artery (MCA) infarct with edema, or bilateral\u002Fmultifocal infarcts, clinically significant vascular malformation, brain tumor, or other central nervous system (CNS) pathology\n* Recent major surgery or trauma (\\\u003C30 days)","ALL","45 Years","80 Years",{"count":21,"type":22},140,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","This is a trial to evaluate the safety and effect of three intravenous (IV) doses of NTS-521 for the early recovery treatment of acute ischemic stroke (AIS). Participants will be followed for 90 days.",[28],"Acute Ischemic Stroke",[28,30,31,32],"AIS","Ischemic Stroke","Stroke","NOT_YET_RECRUITING","2026-07-31",{"date":36,"type":37},"2026-08-03","ACTUAL",{"date":39,"type":22},"2026-10-31",{"date":41,"type":22},"2028-12-15",{"name":43,"class":44},"NeuroTrauma Sciences, LLC","INDUSTRY",""]